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Abstract 
In addition to osteosynthetic stabilizing tech-
niques and autologous bone transplantations,
so-called orthobiologics play an increasing role
in the treatment of bone healing disorders.
Besides the use of various growth factors, more
and more new data suggest that cell-based ther-
apies promote local bone regeneration. For ethi-
cal and biological reasons, clinical application of
progenitor cells on the musculoskeletal system
is limited to autologous, postpartum stem cells.
Intraoperative one-step treatment with autolo-
gous progenitor cells, in particular, delivered
promising results in preliminary clinical studies.
This article provides an overview of the rationale
for, and characteristics of the clinical application
of cell-based therapy to treat osseous defects
based on a review of existing literature and our
own experience with more than 100 patients.
Most clinical trials report successful bone regen-
eration after the application of mixed cell popu-
lations from bone marrow. The autologous appli-
cation of human bone marrow cells which are
not expanded ex vivo has medico-legal advan-
tages. However, there is a lack of prospective
randomized studies including controls for cell
therapy for bone defects. Autologous bone mar-
row cell therapy seems to be a promising treat-
ment option which may reduce the amount of
bone grafting in future. 
Introduction
Treating bone healing disorders represents
a huge challenge for orthopedic and trauma
surgeons and frequently produces unsatisfac-
tory results. Critical size bone defects, in par-
ticular, which appear after tumor surgery or
trauma do not heal spontaneously and require
special therapy. There are also diseases which,
despite surgical intervention and the applica-
tion of all conventional therapies to promote
bone regeneration, are accompanied by insuf-
ficient bone healing. These include aneurys-
mal bone cysts, enchondroma and congenital
pseudarthrosis. In the broadest sense, bone
defects also include avascular osteonecrosis
which is defined by the death of osteoblasts. In
addition to successful bone healing through
the use of growth factors, increasingly positive
results of osseous regeneration through stem
cells have been published in recent years.1 This
article describes the current state of cell-based
therapy for osseous regeneration.Established treatments in bonehealing disordersAutologous bone transplantation
Autologous bone transplantation is the
therapy of choice for treating bone healing
disorders. Despite its high efficiency in regen-
erating bone tissue, autologous (cancellous)
bone transplantation does have numerous dis-
advantages. These include a longer surgery
time, damage by surgical exposure (e.g. sub-
cutaneous nerves), persisting pain and
swelling at the donor site, and impaired
esthetics due to scar formation or osseous
malformation. Furthermore, the potential for
osseous regeneration of autologous bone
grafts in elderly people is low compared to an
increased donor site morbidity in this popula-
tion.2 The growing interest among experts can
also be seen in the increasing number of pub-
lications dealing with donor site morbidity
(Figure 1).Callus distraction
New bone formation in long bones is
achieved using callus distraction, including
the so-called segment transport and external
fixation devices. There must be osseous inter-
ruption which is fracture-related or created by
an osteotomy. Disadvantages include the fact
that the process can continue for months, the
risk of infections transmitted via the pin tracks
of the fixation, and the lack of application pos-
sibilities to the pelvis, spine, thorax, skull or to
the hand and foot skeletons.Ultrasound and shock waves
Using extracorporeal shock wave therapy to
regenerate bone is mostly restricted to treating
atrophic pseudarthrosis. Critical size bone defects
cannot be healed by this non-operative therapy.
Biological fundamentals andrationale of cell-based therapy ofbone defects and bone healing disorders
The rationale for a cell-based therapy to
induce bone tissue regeneration is based on
the high osteogenic potency of undifferentiat-
ed or almost undifferentiated osteoblastic pro-
genitor cells of various origins. This has been
documented in a now vast number of pre-clin-
ical studies.3 For ethical and biological rea-
sons, stem cell therapy on the musculoskeletal
system is limited to autologous transplantation
of postpartum progenitor cells. Omnipotent
(the potential to regenerate a complete, viable
organism) or totipotent (potential to regener-
ate different types of tissue) embryonic stem
cells, on the other hand, are used only in
experimental studies.
Quantitatively relevant amounts of mes-
enchymal, multipotent progenitor cells are
found not only in human bone marrow, but par-
ticularly also in the periosteum and in adipose
tissue.4-6 On the other hand, stem cells with
osteoblastic potency, occur in lesser quantities
in numerous other tissues, such as muscle,7
umbilical cord blood,8 placenta,9 skin,10 carti-
lage11 and synovium.12 Osteoblastic differentia-
tion of mesenchymal stem cells passes through
numerous intermediary stages, whereby it is
less the original tissue of the MSC than the
local environment with correspondingly differ-
ent stimuli that influences the kinetics, gene
expression and protein synthesis of the cells.
The mechanisms of intracellular signal trans-
duction are complex and most clinically orient-
ed orthopedic surgeons can barely grasp the
overall picture (Figure 2). Depending on the
degree of differentiation of the osteoblastic
precursor, different typical proteins and anti-
gens are expressed in different amounts
(Figure 2). As differentiation increases, the
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cellular proliferation rate falls.
Other characteristics which make autolo-
gous mesenchymal progenitor cells an attrac-
tive candidate for the treatment of bone
defects are: 
1. simple availability and an uncomplicated
harvesting technique by aspiration without
the disadvantage of significant harvesting
morbidity;
2. the standardized and well-established isola-
tion technique using density gradient cen-
trifugation or flow cytometry technology
(e.g. fluorescence activated cell sorter,
FACS); 
3. a consensual definition of the term “mes-
enchymal stem cells” (MSC) that has now
been worked out, with well-defined biologi-
cal properties17-19 (Table 1);
4. the simple cultivation technique for in vitro
expansion and determination of the prolif-
eration rate through colony forming units
(CFU);
5. that osteoblastic differentiation can be well
controlled in in vitro cultivation with stimuli
such as dexamethasone, ascorbic acid and
β-glycerol phosphate (DAG), and the
decades of experience with this stimulation
method;
6. the availability of defined cellular expres-
sion markers by which osteoblastic differen-
tiation can be reliably documented (e.g.
osteocalcin, osteopontin, osteoprotegerin,
Cbf1/Runx2, collagen type I, alkaline phos-
phatase, osterix, bone sialo protein, signs of
biomineralization, RANKL);20
7. the immunosuppressive and immunomodu-
latory effects of MSC which lead to a limita-
tion of local inflammatory reactions at the
transplantation site;21
8. the good adherence to surfaces, which
favors the use of scaffolds and advocates
local concentration of in vivo introduced
cells at the transplantation site;22
9. the decades of experience in bone marrow
transplantations in hemato-oncology, which
is supported by the low transplantation risk
especially in autologous transplantations.Clinical application of cell therapiesin bone healing disorders
In contrast to the extensive in vitro and ani-
mal experiment data, there are only a few stud-
ies that show clinical results for cell therapy
treatments to regenerate bone.
There are two clinical application forms of
cell therapies to regenerate bone. Besides the
biological differences, various health law-relat-
ed consequences also emerge for the manufac-
turer and the orthopedic surgeon in attendance.
1. Cell therapies without expansion in culture:
a. with the isolation of defined primary cells;
b. without the isolation of defined primary
cells.
2. Cell therapies with ex vivo expansion:
Review
Figure 1. The increasing frequency of publications on “donor site morbidity” and “bone”
listed by Medline reflects the growing interest and examination of bone harvesting-relat-
ed damage. 
Figure 2. Summary of important intracellular pathways of signal transduction during
osteoblastic differentiation. Cytomechanic stimuli, BMPs and inflammatory stimuli, in
particular, encourage osteoblastic differentiation. The expression of some of the listed KO-
factors, such as  Lef1/Tcf7,13 decreases towards the end of osteogenic differentiation. On
the other hand, other expression factors (e.g. Lef1∆N), increase in terminal osteoblastic
differentiation.14 The differentiation paths of adipoblasts and osteoblasts from a common
progenitor cell separate relatively late, whereby adipose tissue in addition to human bone
marrow is suitable as the original tissue used in cell therapies for bone regeneration.15 Due
to the small or even lack of expression of MHC-II, mesenchymal progenitor cells have a
low immunogenetic potential.16 Moreover, in contrast to other cell types, they have an
immunosuppressive effect on neighboring cells. ALK: activin receptor-like kinase; ALP:
alkaline phosphatase; APC: activated protein C; BMP: bone morphogenic protein; cbfa:
core binding factor; Cdk: cyclin-dependent kinases; CHOP: CCAAT enhancer-binding
protein (C/EBP) homologous protein; CTGF: connective tissue growth factor; cAMP:
cyclic adenosine monophosphate; COX: cyclo-oxygenase; ERK: extracellular signal-related
kinase; LRP: LDL receptor-related protein; MAP: mitogen-activated protein kinase;
MHC: major histocompatibility complex; OAZ: Olf-1/EBF-associated zinc finger;  PG:
prostaglandin(s); PPAR: peroxisome proliferator activated receptor; SF: short form; SnoN:
Ski-related novel oncogene; STAT: transducer and activator of transcription; Tob: transduc-
er of erbB2; VEGF: vascular derived growth factor; Wnt: wingless gene; sFRP: secreted friz-
zled related protein, Lef: lymphoid enhancer binding factor. 
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a. with typical cell differentiation;
b. without typical cell differentiation. 
Cell therapies without expansion inculture
What is generally meant here is cell therapies
that are harvested or produced during an opera-
tion. The tissue used for this does not leave the
operation theatre or operation area and is,
therefore, under the direct supervision and
responsibility of the operator in attendance.
Bone marrow aspiration concentrate (BMAC) is
a typical example of this form of application. At
the beginning of the operation, a defined vol-
ume of bone marrow is harvested by Jamshidi-
vacuum aspiration of the ventral or dorsal iliac
crest and suspended in an anti-coagulating
heparin and ACDA solution in a transfusion
bag. Mononuclear cells are then isolated from
the harvested bone marrow aspirate in a densi-
ty gradient centrifuge in the closed system that
we have been using since 2005. 
Possible quality controls of the cell therapy
(BMAC) are to compare the number of cells in
the BMAC with that in the initial aspirated
bone marrow, and determine the CFU-F and
ALP activity during in vitro cultivation.23-25
Despite these quality parameters, the individ-
ual potency of in vivo applied cell therapies
cannot be reliably predicted. Some publica-
tions indicate, however, that compared to the
transplantation of a defined type of cell, apply-
ing mixed populations of mesenchymal and
hematopoietic progenitor cells at different
stages of differentiation is more effective for
osteogenic regeneration.26
In a prospective clinical study and in various
experimental treatments, our research group
has so far successfully treated over 100
patients with local bone healing disorders
using a BMAC biomaterial composite. Fifty
percent of the bone defects were grafted with
autologous cancellous bone and the remaining
50% with a BMAC biomaterial composite
(hydroxylapatite, Orthoss®, Geistlich,
Wolhusen, Switzerland vs. collagen sponge,
Gelaspon®, Chauvin Ankerpharm, Berlin,
Germany). So far, our study has found that the
use of BMAC reduces the harvest of autoge-
nous bone by 50% with no slowing down or
absence of bone healing being observed.27,28 No
complications with the application were
observed in any of the patients. The low com-
plication risk of this procedure29 and the
osteogenic potency in the parallel application
of different biomaterials has also been report-
ed by other research groups.30,31
A high variance in the number of harvested
cells was observed in the human bone marrow
aspirate.32,33 To maximize the yield of bone mar-
row cells, the following procedure is recom-
mended.
- Create a sufficiently high vacuum: this is
necessary to create sufficient local force to
retrieve the (in contrast to hematopoietic
cells) strongly adherent mesenchymal cells
from the tissue mass. If the vacuum is too
low, the amount of peripheral blood in the
aspirate will be higher. As well as the
plunger pressure created by the operator,
the geometry of the syringe also plays an
important role in creating sufficient nega-
tive pressure (Figure 3).
- Draw several small portions in small aspira-
tion volumes: the number of mesenchymal
progenitors (and the vacuum) per aspira-
tion volume decreases during an aspiration
procedure.34 It is recommended, therefore,
that you draw a maximum 5 mL of bone mar-
row and then create a new vacuum.
- The number of mesenchymal progenitor
cells falls with repeated aspiration proce-
dures at the same spot. A maximum 3 aspi-
rations at the same spot before positioning
the needle at another spot is, therefore, rec-
ommended. 
- More cells are retrieved with parallel inser-
tions of the aspiration needle than with
diverging insertions in one area (Figure 4). 
Also ensure sufficient anti-coagulation of
the bone marrow aspirate during the harvest-
ing procedure. Heparin and ACDA solutions
are used for this. The aspiration needles and
syringes should be flushed with the solution
before use. Density gradient centrifugation is
particularly suitable for isolating mononuclear
cells for bone regeneration therapy.23Cell therapy treatments with tem-porary ex vivo expansion
In orthopedics and traumatology, autologous
cell therapies have been used regularly on the
musculoskeletal system after ex vivo cultiva-
tion, at least since the clinical introduction of
autologous chondrocyte transplantation (ACI).
Unlike cartilage regeneration, for which ACI
was used in more than 12,000 patients
between 1987 and 2005,35,36 there are no reli-
able data on osseous regeneration after tempo-
rary in vitro cultivation. In the treatment of
necrosis of the femoral head, for instance,
Review
Figure 3. In iliac crest-vacuum aspiration,
the geometry of an aspiration syringe influ-
ences the proportion of MSCs in the aspi-
rate. The pressure required to retrieve the
mesenchymal cells is exerted at the tip of the
needle and is defined by the formula: pres-
sure (P) = force (F)/area (A), whereby the
force used to create a vacuum is created by
withdrawing the plunger of the syringe.
This force remains relatively constant.
Narrow, long syringes are, therefore, advan-
tageous when harvesting MSCs using bone
marrow aspiration.   
Figure 4. The areas of the iliac crest reached
by the tip of the aspiration needle if inserted
at diverging angles at the same point over-
lap, so that areas that have been perforated
and aspirated once already are subjected to
the procedure several times. This leads to a
drop in the amount of MSCs per volume of
bone marrow aspirate. If the positions of the
inserted needle are parallel, then new MSC
harvesting areas will always be accessed.
Table 1. Consensual definition of the term “mesenchymal stem cell”. A large number of syn-
onyms exist, however, in scientific literature, e.g. precursors of non-hematopoietic tissue,
colony forming units-fibroblasts, marrow stromal cells, bone marrow stroma/stem cells.
Properties of mesenchymal stem cells
Expression of mesenchymal markers CD49a, CD73, CD90, CD105, CD146, Stro-1,
Expression of matrix receptors CD44, CD29, CD71
Absence of hematopoietic markers CD45, CD34, CD14, CD11b, HLA-DR
Biological properties Spindle-shaped morphology Good adherence to plastic
Evidence of CFU-F
Self-renewal potential
Mesenchymal multipotency (osteoblast, chondroblast, 
adipoblast, myoblast, fibroblast and their precursors)
High proliferation rate, particularly in the presence of 
defined growth factors, e.g. FGF-2
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whereas numerous one-step transplantations
are documented, only three case studies with a
maximal observation period of three months
can be found. Here, a mixed cell population
from bone marrow cells (so-called tissue repair
cells, TRCs), was expanded over 12 days under
GMP conditions and then transplanted autolo-
gously together with a scaffold made of trical-
cium phosphate (TCP) within the framework
of core decompression.37
The particular drawbacks of temporary culti-
vation of MSCs lie not only in the considerable
logistical effort to ensure the quality of the cell
therapy treatment but especially in the biolog-
ical characteristics of this cell population. As
soon as MSCs are isolated from their tissue
mass and transferred to a culture dish, differ-
entiation proceeds in accordance with the cul-
ture conditions.38-40 The yet inconclusive biolog-
ical effects when fetal bovine serum is used in
the culture, as well as telomere shortening,
and thus cell aging with ex vivo cultivation
also have to be considered. Furthermore,
analysis of 170 neoplasia-associated DNA pro-
moters was able to show that despite the rela-
tively high genetic stability of MSCs from
human bone marrow or adipose tissue, dam-
age in the genome could occur at later stages.41
The question as to whether these genotoxic
effects of prolonged in vitro cultivation are also
clinically manifested after re-transplantation
remains unanswered, however. The potential
effects of changes in the chromatin structure
due to epigenetic factors at the beginning of
osteoblastic differentiation also remain largely
unknown.42Cell therapy in local bone defects,bone healing disorders andosteonecrosis
Other research groups have also reported
positive clinical results after using human
bone marrow cells. Giannini et al. showed that
in patients with osteochondral defects in the
talus, functional improvements were achieved
through autologous bone marrow cell trans-
plantation by arthroscopic surgery.43 As early as
1991, Conolly et al.44 reported equivalent heal-
ing rates for autologous bone marrow grafting
to treat post-traumatic pseudarthrosis of the
tibia. Other authors also support the high
osseous regeneration potency of the percuta-
neous implantation of autologous bone mar-
row concentrate to treat pseudarthrosis32,33 and
discuss supplementary osteoblastic stimula-
tion using platelet rich plasma (PRP).45
Some authors, on the other hand, have rea-
son to believe that bone regeneration through
cell therapy also depends very much on the
transplantation site and the local blood supply.
According to a study by Kitho et al., in which ex
vivo -cultivated MSCs were used together with
PRP in 51 lengthening osteotomies, cell thera-
py accelerated bone healing in the femur com-
pared to in the tibia.46 Overall, however, the cell
therapy showed no advantages over the
untreated control group and, moreover, no
relation between the bone healing rate and the
number of transplanted cells or the PRP con-
centration was found. Hernigou et al., howev-
er, reported that grafting over 50,000 osteo -
blastic progenitor cells particularly encouraged
healing in atrophic tibial pseudarthrosis.33
Minimally invasive cell therapy of solitary or
aneuryamal bone cysts via percutaneous
implantation of autologous bone marrow is
favored by a number of authors owing to the
healing rate of over 80%47,48 (Figure 5). On the
other hand, a randomized clinical study
showed that in the treatment of simple bone
cysts, autologous bone marrow injections were
inferior to local steroid injections.49
Initial results are also available on cell ther-
apy treatments to promote osseous fusion at the
spine. After an observation period of 34
months, fusion rates of over 90% were found
for tricalcium phosphate (TCP)-bone marrow
composite transplantations.50 For an HA-colla-
gen-I composite incubated with autologous
bone marrow, the posterolateral lumbal fusion
rate was found to be the same as for autolo-
gous bone transplantation, but fusion rates
were not the same for intracorporeal fusions.51
Cell therapies have been used successfully
to treat avascular osteonecrosis (AVN) for
many years by Hernigou et al.52,53 and, in the
meantime, also by other research teams in
experimental treatments and clinical studies.54-
56 Patients with sickle cell anemia-related AVN,
in particular, benefit from a local injection of
mononuclear bone marrow cells. Patients with
steroid-related AVN have a worse prognosis
when treated with MSCs to regenerate bone.57
The number of implanted cells and their pro-
liferation potency, as measured by the CFU-F,
are positive predictors for successful bone
marrow concentrate therapy in the treatment
of osteonecrosis.52 It is unclear whether the
reduced number of MSCs in the proximal
femur observed in patients with AVN is an
independent risk factor in the development of
an AVN, or is resulting from AVN.57 Other
authors, however, report comparatively high
numbers of osteoblasts in the major trochanter
region with necrosis of the femoral head.58
It has been shown that for ARCO stages I
and II local cell therapy with autologous bone
marrow in combination with core decompres-
sion diminished the risk of a medium-term
progression of necrosis of the femoral head.59
A multi-center study on patients with
peripheral artery disease (PAD) amply docu-
mented that mixed cell populations from
human bone marrow not only have an
osteoblastic but also an angiogenetic effect.60
Because of the lack of control groups, how-
ever, cell therapy is mentioned in the current
S1-recommended treatments of atraumatic
necrosis of the femoral head in adults under
“Operation methods without good documenta-
tion support”.61 Besides direct transplantation
of the cell suspension into the AVN area with-
in the framework of a core decompression, a
cancellous bone graft can also be combined
with the autologous cell therapy.62 For this, a
Krohn hollow mill is used to extract a cylinder
of cancellous bone and the AVN area subjected
Review
Figure 5. Healing course after autologous cell therapy with bone marrow aspiration concen-
trate (“BMAC”) augmented with HA granules in a 4-year old male patient with a large
aneurysmal bone cyst of the proximal femur. Ten months after surgery, relevant new bone for-
mation starting within the transplant is observed in computed tomography  scan (star, *). The
clinical and radiological 3.5 year follow up after treatment showed no recurrence and an
asymptomatic patient. Based on the reduced amount of autologous bone available for graft-
ing, pediatric patients in particular might benefit from the minimally invasive cell therapy.
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Table 2. A summary of published studies including more than 10 patients after cell therapy in bone defects or bone healing disorders.
The medline review showed that cell therapy by bone marrow is not a new technique but has been applied for almost 20 years.
According to the scaffold, causative disease, body region and other patient-related factors, most studies demonstrate promising results
for bone regeneration by bone marrow cells.
Author Year Journal Bone defect N patients Results
Connolly et al.44 1991 CORR Pseudarthrosis 20 Application of autologous bone marrow (BM) in tibial pseudarthrosis or 
“non-union“. Post-operative treatment with plaster cast. Additional 
intramedullary nailing in 10 cases. The authors report that autologous BM 
application produced the same results as for autologous bone transplantation.  
Lokiec et al.63 1996 JBJS-Br Simple 10 Percutaneous injection of autogenous bone marrow: all the patients
bone cysts became pain-free after two weeks and resumed full activities within six 
weeks. The cysts were radiologically consolidated and showed remarkable
remodeling within four months. Bone healing was achieved 12-48 months
after treatment (no complications). 
Köse et al.64 1999 Bull Hosp J T Dis Simple 12 Autologous bone marrow injection in bone cysts: complete healing occurred
bone cysts in 2 patients, whereas 3 cysts showed residual defects. In 6 patient, cysts 
recurred. Authors concluded that factors such as the size, multi-loculation, 
and completeness of the filling of the cyst with bone marrow grafting might 
influence the post-operative outcome.
Hernigou et al.52 2002 CORR AVN (Hip) 116 Evaluation of the clinical outcome 5-10 years after core decompression in
(189 hips) combination with injection of autologous BM concentrate in the treatment 
AVN of the femoral head. Very good results in pre-collapse stages (ARCO
I-II): 9 out of 145 hips were replaced endoprosthetically. In post-collapse
stages, 25 out of 44 hips replaced endoprosthetically. Better results with
higher CFU-F and cell numbers.
Rougraff et al.65 2002 JBJS-Am Unicameral 23 Percutaneous injection of allogeneic demineralized bone matrix augmented
bone cyst with autogenous bone marrow is an effective treatment for unicameral bone cysts.
Chang et al.66 2002 JBJS-Br Unicameral 79 14 patients treated with BM ( 27 injections) vs. 65 patients with steroid
bone cyst application (99 injections). Repeated injections were required in 57% of 
patients after BM had been used and in 49% after steroid. No complications. 
No advantage could be shown for the use of autogenous injection of BM
compared with injection of steroid in the management of unicameral bone cysts.
Price et al.67 2003 Spine Spinal fusion 77 Retrospective study with 3 different bone grafting techniques: autologous 
iliac crest bone graft (ICBG) vs. freeze-dried corticocancellous allograft vs. 
composite graft of autologous bone marrow (BM) and demineralized bone 
matrix. Segmental instrumentation with dual-rod fixation was used in 77 
patients. No BM aspiration-associated morbidity. Fusion rates were 
comparable for ICBG and BM group.
Docquier et al.68 2003 J Pediatr Orthop Simple 17 Percutaneous aspiration and injection of BM. FU: 33.9 months. 
bone cysts Slow regression of the cyst and progressive healing: 13 cases (76%). No 
response: 2 cases (12%), recurrence: 2 cases (12%). 
Gangji et al59 2004 JBJS-Am AVN (hip) 13 Necrosis of the femoral head in ARCO stages I-II. Core decompression 
(18 hips) (vs. core decompression + BM aspirate (10 patients). Within 24 months, 
significant reduction in pain, functional improvement and lower AVN 
progression rate after cell therapy. No transplantation-related 
complications.
Hernigou et al.33 2005 JBJS-Am Pseudarthrosis / 60 Injection of 20 cm3 BM concentrate: 612±34 progenitor cells/cm3 in the
non-unions aspirate compared to 2579±1121 progenitor cells/cm3 after density 
(atrophic, tibia) gradient centrifugation: healing in 53 cases. Positive correlation between
callus regeneration and the number of CFUs.
Kanellopoulos69 2005 J Pediatric Active 19 BM injection in bone cysts. All patients were asymptomatic at the latest 
Orthop unicameral follow up. Two patients required a second intervention to achieve complete 
bone cyst cyst healing. Radiographic outcome was improved in all patients according to
the Neer classification at the latest FU. There were no significant 
complications related to the procedure, nor did any fracture occur after 
initiation of the above regimen.
Neen et al.51 2006 Spine Spinal fusions 50 Therapy using HA-collagen I composite incubated with autologous BM
aspirate (incubation time: 20 min) vs. autologous bone transplantation
The same posterolateral lumbar fusion rates for both groups, similar
functional results for both groups. Autologous bone transplantations raised
the fusion rate in “interbody fusions“, but donor-site morbidity in 14% of the
cases.
Yan et al.70 2006 Chin AVN (hip) 28 Percutaneous multiple hole decompression combined with autologous 
J Traumatol (44 hips) BMCs. The earlier the stage, the better the result. A randomized prospective
study needed in the future to compare with routine core decompression.
Continued next page
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Continued Table 2.
Author Year Journal Bone defect N patients Result
Dallari et al.45 2007 JBJS-Am Proximal 33 Prospective, randomized study with 2 therapy groups: lyophilized bone chips
tibia + PRP (A, 11 patients) vs. lyophilized bone chips + PRP + bone marrow (B, 12
osteotomies patients). Control group: lyophilized bone chips only. CT-controlled biopsies
six weeks post-OP showed increased callus formation in A and B compared 
to the control group. Improved bone healing in A and B within one year.
Deng et al.71 2007 Chin J Regen Bone cyst 13 Transplantation of the autologous bone marrow combined with the allograft
Reconstr Surg bone. Complete healing within 3.5-8 months (Ø 5.2 months). No recurrence,
no pathological fracture occurred. Complete recovery of function.
Cho et al.72 2007 JBJS-Br Bone cysts 28 (58) 30 patients treated by steroid injection vs. 28 individuals by bone marrow 
grafting. Overall success rates: 86.7% vs. 92.0%, respectively (P>0.05). Initial 
success rate: 23.3% in the steroid group vs. 52.0% in the BM group. Mean 
number of procedures:  2.19 (1 to 5) vs. 1.57 (1 to 3) (P<0.05). Average 
healing interval: 12.5 months (4-32)  P =14.3 months (7-36) (P>0.05). Rate of
recurrence after initial procedure: 41.7% vs. 13.3% (P<0.05). Although the 
overall rates of success of both methods were similar, the steroid group 
showed higher recurrences after a single procedure and required more 
injections to achieve healing.
Wright et al.49 2008 JBJS-Am Bone cysts 77 Randomized, prospective study. Two therapy groups: injection of autologous
BM (A) vs. injection of methylprednisolone (B). Healing rate within two
years: 23% (A) vs. 42% (B). No significant difference in the functional outcome.
Park et al.47 2008 Foot Ankle Bone cysts 20 Therapy of unicameral bone cysts of the calcaneus. Two therapy groups: open
(23 cysts) surgery application of avital allogenic donor bone + autologous BM (A) vs. 
injection of demineralized bone powder + autologous BM (B). Healing rate 
within 49.4 months: A: 9 out of 13 cysts vs. B: 5 out of 10 cysts. No infections.
Gan et al.50 2008 Biomaterials Spinal fusions 41 Application of TCP incubated with BM concentrate (duration circa 2 h). 
Concentration factor (CFUs-ALP: 4.3). Drop in MSCs with increasing age, but
no dependency on gender. After 34.5 months, spinal fusion in 95.1% of the
cases. 
Zamzam et al.48 2008 Int Orthop Solitary bone cysts 28 A minimum one-off percutaneous injection of autologous BM. 
No complications. Within 34.7±6.87 months, bone healing in 82% of the cases.
Jäger et al.73 2009 CSCRT Bone defects 10 Significant bone regeneration through bone marrow concentrate (BMAC) in
combination with autologous cancellous bone.
Hendrich et al.29 2009 Orthop Rev Bone defects, AVN 101 Proof of the low complication risk of autologous BMAC in 101 applications.
Giannini et al.43 2009 CORR Osteochondral 48 Functional improvements after arthroscopy-assisted application of 
lesions (talus) autologous BM aspirate in osteochondral defects in the talus.
Sir et al.74 2009 Vnitr Lek Fracture-related bone 11 Local and one-step injection of MSCs from human BM. Results pending.
defects, pseudarthrosis
Kitoh et al.46 2009 J Pediatr Orthop Tibial vs. 28 Retrospective study. Application of ex vivo cultivated MSCs together with PRP
. femoral (51 osteotomies) Control group: 60 patients without MSC/PRP. No stimulation of bone healing
lengthening by MSC/PRP. Worse results for the tibia.
osteotomies
Hernigou et al.56 2009 Indian J Orthop AVN 342 Autologous cell therapy in ARCO stages I-II in combination with a core 
(hip) (534 hips) decompression. After 8-18 years, 94 endoprosthetic hip replacements. 
Predictor for a therapy success was a high number of progenitor cells.
Wang et al.75 2009 Arch AVN 45 BMAC injection in AVN of the femoral head (ARCO stage I-III).
Orthop (hip) (59 hips) Clinically successful in 79.7%. Hip replacement within FU in 11.9%
Trauma of the hips. Radiologically, 14 of the 59 hips exhibited femoral head collapse
Surg or narrowing of the joint space. Overall failure rate: 23.7%. The concentration 
factor of mononuclear cells from BM vs. BMAC was about 3.
Miller et al.76 2010 Int Orthop Non-union 13 Bone marrow cells harvested by a reamer-irrigator-aspirator (RIA) 
or segmental were treated by dexamethason and transplanted into segmental bone 
defect defects. Promising results were achieved using this technique; and given the
complexity of these cases, the observed success is of great value and 
warrants controlled study into both standardization of the procedure and 
concentration of the grafting material.
Yamasaki et al.77 2010 JBJS-Br AVN (hip) 22 (30 hips) Transplantation of bone-marrow-derived mononuclear cells (BMMNCs)
combined with hydroxypapatite (HA) vs. HA only in AVN of the femoral head.
Reduction of the osteonecrotic lesion was observed subsequent to 
hypertrophy of the bone in the transition zone in the BM group. In 3 patients
of the BMMNC group, progression to extensive collapse occurred. Control
group showed bone hypertrophy, but severe collapse of the femoral head
occurred in 6 of 8 hips.
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to curettage through the resulting cavity. After
removing the macroscopic avascular tissue for
histopathological diagnosis, the cylinder of
cancellous bone is incubated with the cell ther-
apy and then re-implanted in the osseous
defect. Medium- and long-term results of this
cell therapy treatment are pending. Table 2 is a
summary of the results of clinical applications
of cell therapies to regenerate bone.Cell therapy in skeletal diseases
In addition to the local application of MSCs,
data are also available for MSCs in the suc-
cessful treatment of skeletal diseases which
are accompanied with deficiencies in the bone
structure.78,79
In 1999, after numerous in vitro experi-
ments and animal experimental studies,
Horwitz et al., for the first time, treated 3 chil-
dren with osteogenesis imperfecta (OI) with
allogenic transplantations of mesenchymal
bone marrow cells.80 The cells were introduced
intravenously after ablative pre-treatment of
the patient (chemotherapy and immunosup-
pression). Post-operative bone biopsies after
216 days and bone density measurements
showed a significant quantitative and qualita-
tive improvement in the bone structure. In
another publication from the year 2001, the
same research group81 reported their findings
on 5 OI patients who had been treated with cell
therapy and on 2 other OI patients without cell
therapy treatment (OI type III). After an inves-
tigation period of six months, children who
had received cell-based therapy showed an
accelerated growth rate. 
Osteopetrosis is another skeletal disease
involving insufficient osteoclast activity that is
currently being treated with autologous bone
marrow transplantation. Driessen et al.82 found
that the probability of 5-year disease free sur-
vival was 73% after cell-based therapy.
Treatment before the age of three years
improved the chances of success of cell thera-
py in osteopetrosis.83 However, due to the
severe side-effects and possible complications
(e.g. graft rejection, hypercalcemic crises, pul-
monary hypertension, delayed hematopoiesis,
veno-occlusive disease), allogeneic cell thera-
py treatment of patients with osteopetrosis is
limited to severe manifestation of disease.84
Three case reports also report the successful
treatment of an 8-month old infant with infan-
tile hypophosphatasia who underwent trans-
plantation of T-cell depleted bone marrow from
the sister. The positive effects of the cell ther-
apy ceased, however, after six months. Twenty-
one months after the first transplantation, a
second transplantation of ex vivo expanded
bone marrow cells took place resulting in an
increase in bone mass. At the age of six, the
patient in question still showed signs of stunt-
ed growth but displayed normal intelligence.85
Another approach in cell therapy treatment of
infantile hypophosphatasia consists of intra -
peritoneal, subcutaneous or intraosseous bone
transplantation from a related donor parallel to
the intravenous bone marrow injection. The
postulate here is that migration of the donor
MSCs in the recipient organism will positively
influence bone healing and the rejection reac-
tions.86,87 It is unclear whether cell-based thera-
py will also gain acceptance in other skeletal
diseases, such as osteoporosis.Outlook for the future
Due to the accelerated aging of osteoblastic
progenitor cells after in vitro cultivation, the
limited resources, the diminished osteoblastic
potency with increasing age and the improved
standardizations, immortalized human MSCs
are currently undergoing pre-clinical investi-
gations for their suitability for cell therapy.88,89
One way of avoiding aging of MSCs is to trans-
fer the cDNA of telomerase reverse transcrip-
tase (hTERT). With this enzyme, the telomeres
that have been shortened during the course of
replication are returned to their original
length. Some authors were able to demon-
strate a high osteoblastic potency in vitro and
in animal experiments with this process.88
Nevertheless, in view of the current legisla-
tion, it is uncertain whether these new thera-
py procedures can also be tested clinically. In
addition to cell-based therapies, there are
other innovative “orthobiologics” with bone
regeneration as the goal. These include anchor
proteins that stimulate osteoblastic adherence,
e.g. RGD sequences, fibronectin or peptide 15.
α-granules of thrombocytes, in particular, con-
tain large amounts of growth factors with
osteoblastic and cell proliferation potency,
such as transforming growth factor-β (TGF),
vascular endothelial growth factor (VEGF) and
platelet-derived growth factor (PDGF).90
Whether it makes sense and is necessary,
within the context of the clinical application of
cell therapies, to increase the osseous potency
of osteoblastic progenitor cells using addition-
al growth factors must first be investigated in
controlled clinical studies given that the hith-
erto existing data are contradictory and not
sufficiently reliable.46,91,92
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